Ovarian carcinoma cells are effectively transfected by polyethylenimine (PEI) derivatives

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 644-652

  Poulain, Laurent ^a   Ziller, Christelle ^a   Muller, Christian D ^b   Erbacher, Patrick ^a   Bettinger, Thierry ^a   Rodier, Jean François ^c   Behr, Jean Paul ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Serv Chir Oncologique Ctr R   (France)

Author keywords

Cancer gene therapy; Gene transfer; Ovarian carcinoma; Polyethylenimine

Indexed keywords

GREEN FLUORESCENT PROTEIN; LUCIFERASE; POLYETHYLENEIMINE DERIVATIVE;

ARTICLE; CANCER THERAPY; CARCINOMA CELL; CONTROLLED STUDY; DRUG STRUCTURE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0034079194     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700170     Document Type: Article

References (36)

1. Barnes MN, Deshane JS, Rosenfels M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol. 1997;89:145-155.
2. Robertson MW, Barnes MN, Rancourt C, et al. Gene therapy for ovarian carcinoma. Semin Oncol. 1998;25:397-406.
3. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ. Gene-directed enzyme prodrug therapy. Bioconjug Chem. 1998;9:4-22.
4. Behbakht K, Benjamin I, Chiu HC, et al. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am J Obstet Gynecol. 1996;175:1260-1265.
5. Rosenfeld ME, Wang M, Siegal GP, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med. 1996;74:455-462.
6. Tong XW, Agoulnik I, Blankenburg K, et al. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus thymidine kinase gene therapy. Anticancer Res. 1997;17:811-813.
7. Tong XW, Block A, Chen SH, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996;61:175-179.
8. McNeish IA, Green NK, Gilligan MG, et al. Virus-directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coll nitroreductase and CB1954. Gene Ther. 1998;5:1061-1069.
9. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
10. Felgner PL, Barenholz Y, Behr JP, et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther. 1997;8: 511-512.
11. Boussif O, Lezoualc'h F, Zanta M-A, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92:7297-7301.
12. Boussif O, Zanta MA, Behr J-P. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther. 1996;3:1074-1080.
13. Abdallah B, Hassan A, Benoist C, Seugnet I, Behr JP, Demeneix BA. A powerful non-viral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther. 1996;7:1947-1954.
14. Ferrari S, Moro E, Pettenazzo A, Behr J-P, Zachello F, Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther. 1997;4:1100-1106.
15. Goula D, Remy J-S, Erbacher P, et al. Size, diffusibility, and transfection performance of linear PEI/DAN complexes in the mouse central nervous system. Gene Ther. 1998;5:172-177.
16. Behr J-P. The proton sponge: a means to enter cells viruses never thought of. Med Sci. 1996;12:56-58.
17. Zanta M-A, Boussif O, Adib A, Behr J-P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem. 1997;8:839-844.
18. Bettinger T, Remy J-S, Erbacher P. Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepatocytes. Bioconjug Chem. 1999;10:558-561.
19. Erbacher P, Remy J-S, Behr J-P. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther. 1999;6:138-145.
20. Kircheis R, Kichler A, Wallner G, et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 1997;4:409-418.
21. Monsigny M, Petit C, Roche AC. Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micro-method. Anal Biochem. 1988;175:525-530.
22. Bénard J, Da Silva J, De Blois M-C, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985;45:4970-4979.
23. Fogh J, Trempe G. New human tumor cell lines. In: Fogh J, ed. Human Tumor Cells In Vitro. New York and London: Plenum Press; 1975:115-159.
24. Poulain L, Lincet H, Duigou F, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell line is linked to a defect in cell cycle control. Int J Cancer. 1998;78:454-463.
25. Behr J-P, Demeneix B, Loeffler J-P, Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA. 1989;86:6982-6986.
26. Erbacher P, Bettinger T, Belguise-Valladier P, et al. Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI). J Gene Med. 1999;1:210-222.
27. Labat-Moleur F, Steffan A-M, Brisson C, et al. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther. 1996;3:1010-1017.
28. v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol. 1996; 62:260-267.
29. 3 integrin in the adhesion of the ovarian adenocarcinoma cell line IGROV1. Int J Cancer. 1995;63:530-536.
30. Blessing T, Remy J-S, Behr J-P. Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc Natl Acad Sci USA. 1998;95:1427-1431.
31. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1997;8:1105-1113.
32. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
33. Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest. 1997;43:268-275.
34. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244-251.
35. Duflot-Dancer A, Piccoli C, Rolland A, Yamasaki H, Mesnil M. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 1998;5:1372-1378.
36. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 1998;5:1705-1711.